European CHMP recommends license extension of nivolumab (Opdivo) plus ipilimumab (Yervoy) for treatment of unresectable malignant pleural mesothelioma

License extension based on results of Checkmate 743 RCT (n=605) which found that nivolumab plus ipilimumab extended overall survival vs chemotherapy (median overall survival 18.1vs 14.1 months, HR 0.74, p=0.0020).

Source:

European Medicines Agency